Saturday, March 31, 2007
perindopril (ACE-inhibitor)
Perindopril versus Angiotensin II Receptor Blockade in Hypertension and Coronary Artery Disease
Posted 03/21/2007
Adrian J.B. Brady
Author Information
Information from Industry
ULTRAM® ER (tramadol HCl) Extended-Release TabletsLearn more about this baseline therapy for adults with moderate to moderately severe chronic pain who need around-the-clock treatment. ULTRAM ER offers proven efficacy with extended pain relief in chronic moderate to moderately severe pain. Review:
* Full Prescribing Information
* Important Safety Information.
Abstract and Introduction
Abstract
The renin-angiotensin-aldosterone system (RAAS) is now known to play a key role in the pathogenesis of hypertension and a range of other cardiovascular diseases. Two groups of drugs, the ACE inhibitors and angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) have been developed with the aim of improving clinical outcomes by regulating the RAAS in patients with cardiovascular disease.
Initial assumptions were that these two drug types might be interchangeable, but ongoing research has revealed differences between them in terms of pharmacology and outcomes in clinical trials. Although both groups of drugs lower blood pressure, studies of the ACE inhibitor perindopril have revealed preservation of beneficial vascular and endothelial effects mediated by bradykinin and nitric oxide. The selective blockade exerted by ARBs is not associated with these effects. Furthermore, examination of clinical endpoints in major clinical trials has provoked discussion about outcomes comparing ACE inhibitors and ARBs, with recent debate focusing on the incidence of myocardial infarction (MI) in patients receiving these agents. Whether there is an actual difference in protection from MI remains unresolved, although available data confirm the benefit and safety of ACE inhibitors, in particular perindopril, for myocardial protection.
Posted 03/21/2007
Adrian J.B. Brady
Author Information
Information from Industry
ULTRAM® ER (tramadol HCl) Extended-Release TabletsLearn more about this baseline therapy for adults with moderate to moderately severe chronic pain who need around-the-clock treatment. ULTRAM ER offers proven efficacy with extended pain relief in chronic moderate to moderately severe pain. Review:
* Full Prescribing Information
* Important Safety Information.
Abstract and Introduction
Abstract
The renin-angiotensin-aldosterone system (RAAS) is now known to play a key role in the pathogenesis of hypertension and a range of other cardiovascular diseases. Two groups of drugs, the ACE inhibitors and angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) have been developed with the aim of improving clinical outcomes by regulating the RAAS in patients with cardiovascular disease.
Initial assumptions were that these two drug types might be interchangeable, but ongoing research has revealed differences between them in terms of pharmacology and outcomes in clinical trials. Although both groups of drugs lower blood pressure, studies of the ACE inhibitor perindopril have revealed preservation of beneficial vascular and endothelial effects mediated by bradykinin and nitric oxide. The selective blockade exerted by ARBs is not associated with these effects. Furthermore, examination of clinical endpoints in major clinical trials has provoked discussion about outcomes comparing ACE inhibitors and ARBs, with recent debate focusing on the incidence of myocardial infarction (MI) in patients receiving these agents. Whether there is an actual difference in protection from MI remains unresolved, although available data confirm the benefit and safety of ACE inhibitors, in particular perindopril, for myocardial protection.
# posted by roodbont @ 3:17 PM 
